The COVID19 disease in Very Elderly Intensive care Patients (COVIP) study
The first part of the recruitment period ended May 26th.
Please enter all data you have for patients included until and on May 26h soon.
Please enter their 30-day survival status no later than June 26th.
Please enter their 3-month survival status and EQ5-5D-5L questionnarie no later than August 26h.
Patient recruitment continues during the summer and fall (until further notice). Thanks for your efforts!
The coronavirus SARS-CoV-2 is currently affecting millions of people across the world and there is an urgent need to investigate patient characteristics and outcome trajectories. Preliminary reports of critically ill COVID-19 patients in Wuhan (China) and Italy have reported a high risk of death in patients with multimorbidity. Also, very old patients with SARS-CoV-2 infections suffered from high mortality rates (1). It is, however, unclear if age alone is an independent risk factor, or if co-morbiditites and frailty trigger the adverse outcome. During the pandemic, treating and triaging elderly COVID-19 may challenge our health care systems.
In non-COVID-19 elderly patients admitted to the ICU, our European research group (2) found that the co-factors are more important than chronological age itself (3, 4).
In patients with COVID-19, pretreatment with angiotensin-blockers and ACE-inhibitors (5) and nonsteroidal anti-inflammatory drugs such as ibuprofen (6) were suggested to be associated with adverse outcome. Furthermore, some groups have reported a higher death rate in patients with concomitant cardiovascular disease (7) and diabetes (8).
This international, multicenter study group (VIP-network) which has previously (2016-2019) conducted the most extensive prospective studies (VIP1, VIP2) on elderly ICU patients will conduct a prospective, observational study to examine the relationship between age, co-morbidities, pretreatment frailty and outcomes in a group of elderly patients receiving critical care for COVID-19.
The results will be essential to understand which factors can predict mortality in elderly COVID-19 patients to help to detect these patients early. Furthermore, this study will also be a knowledge base necessary to guide triage decisions in the future. With this pandemic likely to continue for 18 months, it is paramount to identify independent risk factors early to facilitate both risk stratification and substantiate necessary triage decisions. The pandemic begins in many countries worldwide now, and a decisive action of the research community is needed.
Questions and answers
What is the most important rule for patient registration?
Every patient should only be registered only once in the database, regardless of readmission, transfer or anything else.
How to handle re-admissions in the same hospital?
The patient is once in the database. Readmission to the ICU or transfer to another ICU will be summed up within one CRF/eCRF.
How should time values / time points be recorded in re-admitted patients?
The reference point is always the day of first admission to an ICU. This is the reference for all the other time specifications. A COVID-19-associated re-admission is NOT documented explicitly since this is not possible due to the pragmatic study design. If the readmission is unrelated to COVID-19, the readmission will not be documented.
How to deal with patients who were transferred from another ICU that participates in COVIP?
The most important rule is that patients must only be registered once in the database. If patients are transferred from one ICU to another for capacities and/or ECMO please follow these hints:
- In general, treat consecutive/connected admissions to two ICUs as one admission.
- Register across both ICUs as one admission, if possible.
- The day of admission is the admission day to the first ICU.
- The duration of treatments and ICU length of stay are cumulated across both ICUs.
How to deal with patients who were transferred from a hospital that does not participate in COVIP?
- Kindly consider asking the sending hospital/ICU for COVIP-participation.
- Try to retrieve the relevant information from the documentation of the sending hospital.
- Try to proceed as recommended in answer 4).
- If treatment details from the sending ICU cannot be retrieved (initial ABG, SOFA, CFS, durations etc.) documentation should be completed as detailed as possible.
How to deal with patients who are transferred to a hospital/ICU that does not participate in COVIP?
- Kindly consider asking the receiving hospital/ICU for COVIP-participation.
- Try to retrieve the relevant information from the documentation of the receiving hospital (e.g. letter of discharge).
- In any case, retrieve survival outcomes if possible.
- If treatment details from the receiving ICU cannot ultimately be retrieved (durations etc.) register only treatment details for the sending ICU and/or information as detailed as possible.
How to deal with patients who are re-transferred after the intermediate/temporary treatment in another ICU that does not participate in COVIP?
- Kindly consider asking the sending ICU for COVIP-participation.
- Try to retrieve the relevant information from the documentation of the intermediate hospital (e.g. letter of discharge).
- In any case, retrieve survival outcomes if possible.
- If treatment details from the sending ICU cannot be ultimately be retrieved (durations etc.) register only details that are available.
- (some countries can get outcomes from electronic records even though they can’t get treatment details from the receiving ICU).
Is informed consent mandatory for inclusion?
This differs from country to country depending on local law. The principle investigator is located in Germany with mandatory informed consent. However, some countries do not need informed consent. Please follow your local laws and conditions of your local ethical approval strictly. In case there are any questions, your country coordinator is the local expert.
How to define withholding or withdrawing therapy?
Withholding treatment is defined as the decision not to start or escalate a life-sustaining intervention, such as not to perform CPR if a patient had a cardiac arrest or to decide not treat with renal replacement therapy. Withdrawing treatment is defined as a decision to stop a life-sustaining intervention presently being given, such as stopping a norepinephrine infusion knowing that the patient may not survive without the treatment.
I am the study nurse, but only my PI is registered in the database. How can I help to complete the data of my patients?
Each ICU has one login for patient data entry. The ICUs primary local investigator (primary contact) may delegate the task of data entry to someone else at that site. Please ask your primary local investigator for the login credentials.
How is therapy with high-flow nasal cannula (HFNC) coded in the database?
Although different opinions exit about this, HFNC is considered as oxygen therapy without active pressure support in this study. Therefore, is should also NOT be coded as non-invasive mechanical ventilation (NIV).
How is therapy with Continuous Positive Airway Pressure (CPAP) coded in the database?
CPAP therapy as used in obstructive sleep apnea patients is not considered an intervention of intensive care medicine. If this is applied (e.g. in a patient also receiving this treatment outside the ICU) it should NOT be coded as non-invasive mechanical ventilation. Since we do not assess the exact settings of the machine, the decision of considering the treatment as non-invasive mechanical ventilation is left to the treating physician.
What is the patient already has a tracheostomy at ICU admission?
In the CRF please mark “Tracheostomy” = yes and “Start of tracheostomy” = 8888 (se helper note below data entry field).
Country coordinators and steering group
|Christian Jung||Principle Investigator of the COVIP study and German coordinator||Dusseldorf, Germany||christian . jung @ med . uni-duesseldorf . de|
|Jesper Fjølner||Co-Principle investigator in the COVIP study, Danish coordinator, datamanager||Aarhus, Denmark||jespfjoe @ rm . dk|
|Hans Flaatten||Principal Investigator of the VIP study group, Past chair HSRO section,||Bergen, Norway||hans . flaatten @ uib . no|
|Antonio Artigas||Spanish coordinator||Barcelona, Spain||aartigas @ tauli . cat|
|Bernardo Bollen Pinto||Swiss coordinator||Geneva, Switzerland||bernardo . bollenpinto @ hcuge . ch|
|Bertrand Guidet||Co-Principal Investigator of the VIP study group and French coordinator||Paris, France||bertrand . guidet @ aphp . fr|
|Brian Marsh||Irish coordinator||Dublin, Ireland||bmarsh @ mater . ie|
|Dylan deLange||The Netherlands coordinator and Chair of ESICM HSRO section||Utrecht, The Netherlands||d . w . delange @ umcutrecht . nl|
|David Dudzinski||USA coordinator||Boston, Massachusetts , United States of America||ddudzinski @ mgh . harvard . edu|
|Finn Andersen||Norwegian coordinator||Ålesund, Norway||finn . h . andersen @ helse-mr . no|
|Michael Joannidis||Austrian coordinator||Innsbruck, Austria||michael . joannidis @ i-med . ac . at|
|Matjaž Jereb||Slovenia coordinator||Ljubljana, Slovenia||matjaz . jereb @ kclj . si|
|Rokas Serpytis||Lithuanian coordinator||Vilnius, Lithuania||rserpytis @ gmail . com|
|Muhammed Elhadi||Lybian coordinator||Tripoli, Libya||muhammed . elhadi . uot @ gmail . com|
|Rui Moreno||Portuguese coordinator||Lisboa, Portugal||r . moreno @ mail . telepac . pt|
|Sigal Sviri||Israeli coordinator||Jerusalem, Israel||sigal . sviri @ gmail . com|
|Sandra Oeyen||Belgium coordinator||Ghent, Belgium||sandra . oeyen @ ugent . be|
|Sten Walther||Swedish coordinator||Linkoping, Sweden||sten . walther @ telia . com|
|Susannah Leaver||United Kingdom coodinator||London, England||susannahleaver @ nhs . net|
|Tilemachos Zafeiridis||Greek coordinator||Larissa, Greece||tilemachos @ hotmail . com|
|Wojciech Szczeklik||Polish coordinator||Krakow, Poland||wszczeklik @ gmail . com|
|Yuriy Nalapko||Ukranian coordinator||Lugansk, Ukraine||nalapko @ ukr . net|
|Ariane Boumendil||Statistician||Paris, France||ariane . boumendil @ gmail . com|
|Bernhard Wernly||Co-Investigator and scientific support||Salzburg, Austria||bernhard @ wernly . net|
|Raphael R. Bruno||Co-Investigator and scientific support||Düsseldorf, Germany||raphael . bruno @ med . uni-duesseldorf . de|
Clinical Frailty Scale
The Clinical Frailty Scale (CFS) is a simple point scale with short descriptions and visualizations of levels of frailty. †The CSF is composed of nine classes from very fit to terminally ill. The English version is used for this study.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
- Flaatten H, de Lange DW, Artigas A, Bin D, Moreno R, Christensen S, et al. The status of intensive care medicine research and a future agenda for very old patients in the ICU. Intensive Care Med. 2017;43(9):1319-28.
- Flaatten H, De Lange DW, Morandi A, Andersen FH, Artigas A, Bertolini G, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (>/= 80 years). Intensive Care Med. 2017;43(12):1820-8.
- Guidet B, de Lange DW, Boumendil A, Leaver S, Watson X, Boulanger C, et al. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study. Intensive Care Med. 2020;46(1):57-69.
- [Available from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
- Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086.
- Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.